Lionel B. Ivashkiv, M.D., is Appointed Chief Scientific Officer at Hospital for Special SurgeryMay 5, 2015
NEW YORK, May 5, 2015 /PRNewswire/ — Lionel B. Ivashkiv, M.D., premier scientist in autoimmune, inflammatory and musculoskeletal diseases at Hospital for Special Surgery (HSS) has been named its third Chief Scientific Officer. The announcement was made today by Louis A. Shapiro, president and CEO, and Todd J. Albert, M.D., surgeon-in-chief and medical director, at HSS.
“I am honored to work even more closely with colleagues who are committed to building on HSS’ tradition of interdisciplinary translational research,” said Dr. Ivashkiv. “Together we will advance Special Surgery’s research mission to translate breakthrough findings into new ways of treating and preventing serious orthopedic and rheumatic conditions.”
Currently the David H. Koch Chair in Arthritis and Tissue Degeneration and Associate Chief Scientific Officer, Dr. Ivashkiv succeeds Steven R. Goldring, M.D., who has served as the Chief Scientific Officer since 2006. When Dr. Ivashkiv assumes his new role on June 1, it will also mark his 23rd anniversary at Hospital for Special Surgery.
“I’m delighted that Lionel Ivashkiv will assume leadership of the research enterprise at HSS,” said Thomas Kelly, M.D., HSS board member and Research Committee Chair. “The opportunities for scientific advances in understanding and treating musculoskeletal diseases have never been…
Originally posted on PR Newswire
Read @ PR Newswire